Sökning: onr:"swepub:oai:DiVA.org:uu-512637" > IGFBP-7 and Outcome...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04861naa a2200733 4500 | |
001 | oai:DiVA.org:uu-512637 | |
003 | SwePub | |
008 | 240522s2023 | |||||||||||000 ||eng| | |
009 | oai:gup.ub.gu.se/323085 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5126372 URI |
024 | 7 | a https://doi.org/10.1016/j.jchf.2022.09.0042 DOI |
024 | 7 | a https://gup.ub.gu.se/publication/3230852 URI |
040 | a (SwePub)uud (SwePub)gu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Adamson, Carly4 aut |
245 | 1 0 | a IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction :b Findings From DAPA-HF. |
264 | 1 | b Elsevier BV,c 2023 |
338 | a print2 rdacarrier | |
520 | a BACKGROUND: Insulin-like growth factor-binding protein-7 (IGFBP-7) has been proposed as a potential prognostic biomarker in heart failure (HF), but the association between elevation in IGFBP-7 and HF outcomes in ambulant patients with heart failure with reduced ejection fraction (HFrEF) is unknown. OBJECTIVES: The authors addressed this question in a post hoc analysis of the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) trial. METHODS: The primary outcome was a composite of cardiovascular death or a worsening HF event. The risk of adverse outcome was compared across tertiles of IGFBP-7 concentration by means of Cox proportional hazard models adjusted for N-terminal pro-B- type natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (hsTnT). The efficacy of randomized treatment across IGFBP-7 tertiles was assessed. Change in IGFBP-7 at 12 months was compared with the use of geometric means. RESULTS: A total of 3,158 patients had IGFBP-7 measured at baseline, and 2,493 had a repeated measure at 12 months. Patients in the highest tertile of IGFBP-7 had evidence of more advanced HFrEF. The adjusted HR for the primary endpoint in tertile 3, compared with tertile 1, was 1.48 (95% CI: 1.17-1.88). There was no modification of the benefit of dapagliflozin by baseline IGFBP-7 (P interaction = 0.34). Dapagliflozin did not change IGFBP-7 levels over 1 year (P = 0.34). CONCLUSIONS: Higher IGFBP-7 in patients with HFrEF was associated with worse clinical profile and an increased risk of adverse clinical outcomes. IGFBP-7 provided prognostic information incremental to clinical variables, NT-proBNP, and hsTnT. The benefit of dapagliflozin was not modulated by IGFBP-7 level. (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure [DAPA-HF]; NCT03036124). | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng |
653 | a *Heart Failure/drug therapy | |
653 | a *Ventricular Dysfunction | |
653 | a Left | |
653 | a biomarker | |
653 | a dapagliflozin | |
653 | a heart failure | |
653 | a Humans | |
653 | a Insulin-Like Growth Factor Binding Proteins | |
653 | a insulin-like growth factor-binding protein-7 | |
653 | a Proportional Hazards Models | |
653 | a SGLT2 inhibitor | |
653 | a Stroke Volume | |
700 | 1 | a Welsh, Paul4 aut |
700 | 1 | a Docherty, Kieran F.4 aut |
700 | 1 | a de Boer, Rudolf A.4 aut |
700 | 1 | a Diez, Mirta4 aut |
700 | 1 | a Drozdz, Jaroslaw4 aut |
700 | 1 | a Dukat, Andre4 aut |
700 | 1 | a Inzucchi, Silvio E.4 aut |
700 | 1 | a Kober, Lars4 aut |
700 | 1 | a Kosiborod, Mikhail N.4 aut |
700 | 1 | a Ljungman, Charlotta,d 1977u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine4 aut0 (Swepub:gu)xljcha |
700 | 1 | a Martinez, Felipe A.4 aut |
700 | 1 | a Ponikowski, Piotr4 aut |
700 | 1 | a Sabatine, Marc S.4 aut |
700 | 1 | a Morrow, David A.4 aut |
700 | 1 | a Lindholm, Daniel4 aut |
700 | 1 | a Hammarstedt, Ann4 aut |
700 | 1 | a Boulton, David W.4 aut |
700 | 1 | a Greasley, Peter J.4 aut |
700 | 1 | a Langkilde, Anna Maria4 aut |
700 | 1 | a Solomon, Scott D.4 aut |
700 | 1 | a Sattar, Naveed4 aut |
700 | 1 | a McMurray, John J. V.4 aut |
700 | 1 | a Jhund, Pardeep S.4 aut |
710 | 2 | a Göteborgs universitetb Institutionen för medicin, avdelningen för molekylär och klinisk medicin4 org |
773 | 0 | t JACC. Heart failured : Elsevier BVg 11:3, s. 291-304q 11:3<291-304x 2213-1779x 2213-1787 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-512637 |
856 | 4 8 | u https://doi.org/10.1016/j.jchf.2022.09.004 |
856 | 4 8 | u https://gup.ub.gu.se/publication/323085 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy